For Immediate Release


Representative: Joji Nakayama, President and CEO
(Code no.: 4568, First Section, Tokyo Stock Exchange)
Please address inquiries to Noriaki Ishida, Corporate Officer,
Vice President, Corporate Communications Department
Telephone: +81-3-6225-1126

Daiichi Sankyo Receives Approval for the Use of Inavir® to Prevent Influenza

Tokyo, Japan (December 20, 2013) – Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo), announced today that it received approval in Japan to market Inavir® Dry Powder Inhaler 20mg (generic name: Laninamivir Octanoate Hydrate) for the prevention of influenza in both adults and children.


Inavir® is a long-acting neuraminidase inhibitor developed by Daiichi Sankyo which is manufactured in Japan. The drug was originally launched in Japan for treatment of influenza A and B in October 2010.


Daiichi Sankyo has great expectations for the additional influenza prevention indication for Inavir®, which will provide an additional option for the public to protect themselves against the influenza virus and allow Daiichi Sankyo to further contribute to the health of society.


Product overview

Drug name

Inavir® Dry Powder Inhaler 20mg

Date of approval for partial changes

December 20, 2013

Indications and usage (additional approval underlined)

Treatment and prevention of influenza A and B viruses

Dosage and administration (additional approval underlined)

1. For treatment of the influenza virus

Adults: A single inhaled dose of 40 mg of laninamivir octanoate

Children: If less than 10 years old, a single inhaled dose of 20 mg of laninamivir octanoate

If 10 years old or older, a single inhaled dose of 40 mg.

2. For prevention of the influenza virus

Adults and children over 10 years of age: Daily single inhaled dosage of 20 mg of laninamivir octanoate for two days